Home › Compare › AUDYF vs ABBV
AUDYF yields 2.93% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, AUDYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AUDYF + ABBV for your $10,000?
Ausnutria Dairy Corporation Ltd, an investment holding company, primarily engages in the research and development, milk collection, processing, production, packaging, marketing, and distribution of infant formula and other dairy products. The company operates in two segments, Dairy and Related Products, and Nutrition Products. It offers cow milk-based formula products under the Allnutria, Hyproca Hollary, Hyproca Hypure, Neolac, and Puredo brand names; and goat milk-based infant formula products under the Kabrita brand. The company also produces formula milk powder products on an original equipment manufacturing basis. In addition, it engages in the manufacturing and distribution of nutrition products; development, distribution, and sale of probiotic products; and provision of financing services. The company operates in the People's Republic of China, the European Union, Southeast Asia, Australia, New Zealand, the Middle East, North and South America, and internationally. The company was founded in 2003 and is based in Sheung Wan, Hong Kong. Ausnutria Dairy Corporation Ltd operates as a subsidiary of HongKong Jingang Trade Holding Company Limited.
Full AUDYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.